TIDMFIPP
RNS Number : 7055N
Frontier IP Group plc
01 October 2021
The information contained within this announcement is deemed by
the Group to constitute inside information as stipulated under the
Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations
2019/310 ("MAR"). With the publication of this announcement via a
Regulatory Information Service, this inside information is now
considered to be in the public domain.
RNS
AIM: FIPP
01 October 2021
Frontier IP Group Plc
("Frontier IP" or the "Group")
Portfolio news - Pricing of initial public offering of
Exscientia in the United States
Further to the announcement released on 27 September 2021,
Frontier IP, a specialist in commercialising intellectual property,
notes that its portfolio company Exscientia plc ("Exscientia") has
announced today the pricing of its initial public offering of
13,850,000 American Depositary Shares ("ADSs") at a public offering
price of $22 per ADS. Exscientia has raised gross proceeds of
approximately $304.7 million.
In addition, Exscientia announced the concurrent sale of an
additional 7,272,727 ADSs at the initial offering price of $22.00
per ADS, for gross proceeds of $160.0 million, in private
placements to SVF II Excel (DE) LLC, or Softbank, and the Bill
& Melinda Gates Foundation.
The offering is expected to close on or about 05 October 2021
subject to customary closing conditions and the ADSs of Exscientia
are expected to begin trading on the Nasdaq Global Select Market on
01 October 2021. Each ADS represents one ordinary share in
Exscientia.
A registration statement relating to these securities became
effective on September 30, 2021 and can be accessed here:
https://www.sec.gov/Archives/edgar/data/1865408/000110465921119607/tm2119783-11_f1a.htm
From admission, Frontier IP will be interested in 1,564,800 ADSs
in Exscientia. Based on the initial public offering price of $22
per ADS, Frontier IP's holding is valued at $34.4 million.
The full Exscientia announcement is below.
Further announcements will be made by Frontier IP at the
appropriate time.
Exscientia statement begins:
Exscientia Announces Pricing of $304.7 Million Upsized Initial
Public Offering and $160.0 Million Concurrent Private
Placements
OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq:
EXAI), an AI-driven pharmatech company committed to discovering,
designing and developing the best possible drugs in the fastest and
most effective manner, today announced the pricing of its upsized
initial public offering in the United States of 13,850,000 American
Depositary Shares ("ADSs") representing 13,850,000 ordinary shares
at an initial public offering price of $22.00 per ADS, for total
gross proceeds of approximately $304.7 million. All ADSs sold in
the offering were offered by Exscientia. The ADSs are expected to
begin trading on the Nasdaq Global Select Market on October 1, 2021
under the ticker symbol "EXAI." In addition, Exscientia has granted
the underwriters a 30-day option to purchase up to an additional
2,077,500 ADSs at the initial public offering price, less
underwriting discounts and commissions. The offering is expected to
close on or about October 5, 2021, subject to customary closing
conditions.
In addition to the ADSs sold in the public offering, the Company
announced the concurrent sale of an additional 7,272,727 ADSs at
the initial offering price of $22.00 per ADS, for gross proceeds of
$160.0 million, in private placements to SVF II Excel (DE) LLC, or
Softbank, and the Bill & Melinda Gates Foundation. The sale of
these ADSs will not be registered under the Securities Act of 1933,
as amended, and will be subject to a 180-day lock-up agreement.
Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, BofA
Securities and Barclays Capital Inc. are acting as joint
book-running managers for the offering.
A registration statement relating to these securities became
effective on September 30, 2021. The offering will be made only by
means of a prospectus. When available, copies of the final
prospectus related to the offering can be obtained from any of the
joint book-running managers for the offering: Goldman Sachs &
Co. LLC, Attn: Prospectus Department, 200 West Street, New York,
New York 10282, telephone: 866-471-2526, facsimile: 212-902-9316,
e-mail: prospectus-ny@ny.email.gs.com; Morgan Stanley & Co.
LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, New York 10014, by telephone at 866-718-1649 or by email at
prospectus@morganstanley.com; BofA Securities, NC1-004-03-43, 200
North College Street, 3rd Floor, Charlotte, NC 28255-0001,
Attention: Prospectus Department, or email:
dg.prospectus_requests@bofa.com; or Barclays Capital Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
New York 11717, by telephone at 1-888-603-5847 or by email at
barclaysprospectus@broadridge.com. For the avoidance of doubt, such
prospectus will not constitute a "prospectus" for the purposes of
the Regulation (EU) 2017/1129 and has not been reviewed by any
competent authority in any member state in the European Economic
Area or the United Kingdom.
A registration statement relating to these securities has been
filed with, and declared effective by, the U.S. Securities and
Exchange Commission (the "SEC"). Copies of the registration
statement can be accessed through the SEC's website at www.sec.gov.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy securities, and shall not
constitute an offer, solicitation or sale in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that
jurisdiction.
In any member state of the European Economic Area (the "EEA")
this announcement and any offering are only addressed to and
directed at persons who are "qualified investors" ("Qualified
Investors") within the meaning of the Prospectus Regulation
(Regulation (EU) 2017/1129). In the United Kingdom, this
announcement and any offering are only addressed to and directed at
persons who are "qualified investors" within the meaning of the UK
Prospectus Regulation (Regulation (EU) 2017/1129 as if forms part
of domestic law by virtue of the European Union (Withdrawal) Act
2018) (i) who have professional experience in matters relating to
investments falling within Article 19(5) of the Financial Services
and Markets Act 2000 (Financial Promotion) Order 2005, as amended
(the "Order"), (ii) high net worth entities who fall within Article
49(2)(a) to (d) of the Order, or (iii) to whom it may otherwise
lawfully be communicated (all such persons being referred to as
"relevant persons").
This announcement must not be acted on or relied on (i) in the
United Kingdom, by persons who are not relevant persons, and (ii)
in any member state of the EEA, by persons who are not Qualified
Investors. Any investment or investment activity to which this
announcement relates is available only to and will only be engaged
with (i) in the United Kingdom, relevant persons, and (ii) in any
member state of the EEA, Qualified Investors.
About Exscientia
Exscientia is an AI-driven pharmatech company committed to
discovering, designing and developing the best possible drugs in
the fastest and most effective manner. Exscientia developed the
first-ever functional precision oncology platform to successfully
guide treatment selection and improve patient outcomes in a
prospective interventional clinical study, as well as to progress
AI-designed small molecules into the clinical setting. Our pipeline
demonstrates our ability to rapidly translate scientific concepts
into precision-designed therapeutic candidates, with more than 25
projects advancing, including the first three AI-designed drug
candidates to enter Phase 1 clinical trials.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including statements with
regard to Exscientia's expectations regarding the commencement of
trading of ADSs on The Nasdaq Global Select Market and the
completion of the proposed securities offering. Words such as
"anticipates," "believes," "expects," "intends, " "projects,"
"anticipates," and "future" or similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are subject to the inherent uncertainties in predicting
future results and conditions and no assurance can be given that
the proposed securities offering discussed above will be
consummated on the terms described or at all. Completion of the
proposed offering and the terms thereof are subject to numerous
factors, many of which are beyond the control of Exscientia,
including, without limitation, market conditions, failure of
customary closing conditions and the risk factors and other matters
set forth in Exscientia's filings with the SEC. Exscientia
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be required by law.
Investors:
Sara Sherman
investors@exscientia.ai
Media:
Amanda Galgay
media@exscientia.ai
Exscientia statement ends
ENQUIRIES
Frontier IP Group Plc T: 020 3968 7815
Neil Crabb, Chief Executive neil@frontierip.co.uk
Andrew Johnson, Communications & Investor andrew.johnson@fronterip.co.uk
Relations M: 07464 546 025
Company website: www.frontierip.co.uk
Allenby Capital Limited (Nominated Adviser) T: 0203 328 5656
Nick Athanas / George Payne
Singer Capital Markets (Broker)
Sandy Fraser / Harry Gooden / George Tzimas T: 0207 496 3000
ABOUT FRONTIER IP
Frontier IP unites science and commerce by identifying strong
intellectual property and accelerating its development through a
range of commercialisation services. A critical part of the Group's
work is involving relevant industry partners at an early stage of
development to ensure technology meets real world demands and
needs.
The Group looks to build and grow a portfolio of equity stakes
and licence income by taking an active involvement in spin-out
companies, including support for fund raising and collaboration
with relevant industry partners at an early stage of
development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PFUGLBDGIUGDGBB
(END) Dow Jones Newswires
October 01, 2021 02:59 ET (06:59 GMT)
Frontier IP (AQSE:FIPP.GB)
過去 株価チャート
から 12 2024 まで 1 2025
Frontier IP (AQSE:FIPP.GB)
過去 株価チャート
から 1 2024 まで 1 2025
